ATE531707T1 - Isochinolin- und benzoähüisochinolin-derivate, herstellung und therapeutische verwendung davon als antagonisten des histamin-h3-rezeptors - Google Patents

Isochinolin- und benzoähüisochinolin-derivate, herstellung und therapeutische verwendung davon als antagonisten des histamin-h3-rezeptors

Info

Publication number
ATE531707T1
ATE531707T1 AT06829734T AT06829734T ATE531707T1 AT E531707 T1 ATE531707 T1 AT E531707T1 AT 06829734 T AT06829734 T AT 06829734T AT 06829734 T AT06829734 T AT 06829734T AT E531707 T1 ATE531707 T1 AT E531707T1
Authority
AT
Austria
Prior art keywords
benzohisoquinoline
histamine
isoquinoline
antagonists
receptor
Prior art date
Application number
AT06829734T
Other languages
English (en)
Inventor
Martin Juan Antonio Diaz
Arenales Beatriz Escribano
Bargueno Maria Dolores Jimenez
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Application granted granted Critical
Publication of ATE531707T1 publication Critical patent/ATE531707T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT06829734T 2005-11-24 2006-11-22 Isochinolin- und benzoähüisochinolin-derivate, herstellung und therapeutische verwendung davon als antagonisten des histamin-h3-rezeptors ATE531707T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05111248A EP1790646A1 (de) 2005-11-24 2005-11-24 Isoquinolin- und Benzo[h]isoquinolinderivate, deren Herstellung und deren therapeutischen Verwendung als Antagonisten des Histamin-H3-Rezeptors .
PCT/EP2006/012246 WO2007060027A1 (fr) 2005-11-24 2006-11-22 Derives de isoquinoline et benzo[h]isoquinoline, leur preparation et leur utilisation en therapeutique en tant qu’antagonistes du recepteur de l’histamine h3

Publications (1)

Publication Number Publication Date
ATE531707T1 true ATE531707T1 (de) 2011-11-15

Family

ID=36295552

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06829734T ATE531707T1 (de) 2005-11-24 2006-11-22 Isochinolin- und benzoähüisochinolin-derivate, herstellung und therapeutische verwendung davon als antagonisten des histamin-h3-rezeptors

Country Status (24)

Country Link
US (1) US7678807B2 (de)
EP (2) EP1790646A1 (de)
JP (1) JP5165578B2 (de)
KR (1) KR101386318B1 (de)
CN (1) CN101312961B (de)
AR (1) AR057615A1 (de)
AT (1) ATE531707T1 (de)
AU (1) AU2006316706B2 (de)
BR (1) BRPI0618971A2 (de)
CA (1) CA2630655C (de)
CY (1) CY1112386T1 (de)
DK (1) DK1960387T3 (de)
DO (1) DOP2006000253A (de)
ES (1) ES2376894T3 (de)
GT (1) GT200600490A (de)
IL (1) IL191214A (de)
PE (1) PE20070827A1 (de)
PL (1) PL1960387T3 (de)
PT (1) PT1960387E (de)
RU (1) RU2418794C2 (de)
SI (1) SI1960387T1 (de)
TW (1) TW200738681A (de)
UY (1) UY29971A1 (de)
WO (1) WO2007060027A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2870846B1 (fr) 2004-05-25 2006-08-04 Sanofi Synthelabo Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique
EP2569296A1 (de) * 2010-05-11 2013-03-20 Sanofi Substituierte n-phenyl-spirolactam-bipyrrolidine, ihre zubereitung und therapeutische verwendung
TW201206939A (en) 2010-05-11 2012-02-16 Sanofi Aventis Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof
TW201202251A (en) 2010-05-11 2012-01-16 Sanofi Aventis Substituted N-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof
JP2013529198A (ja) * 2010-05-11 2013-07-18 サノフイ 置換されたｎ−ヘテロシクロアルキルビピロリジニルフェニルアミド誘導体、その製造及び治療上の使用
EP2647377A1 (de) 2012-04-06 2013-10-09 Sanofi Verwendung eines H3-Rezeptorantagonisten zur Behandlung von Morbus Alzheimer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200002904T2 (tr) * 1998-04-10 2001-02-21 Japan Tobacco Inc. Amidin bileşikleri
WO2000023437A1 (en) * 1998-10-16 2000-04-27 Takeda Chemical Industries, Ltd. Nitrogenous fused heterocycle compounds, process for the preparation thereof and agents containing the same
CZ20021911A3 (cs) * 1999-12-03 2002-10-16 Kyoto Pharmaceutical Industries, Ltd. Nové heterocyklické sloučeniny a jejich soli a jejich vyuľití v lékařství
WO2002076925A2 (en) * 2001-03-23 2002-10-03 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
NL1020155C2 (nl) * 2002-03-11 2003-09-17 Bernardus Johannes Jos Bekkers Inrichting voor het dragen van een golftas alsmede werkwijze voor het vervaardigen ervan.
GB0206033D0 (en) * 2002-03-14 2002-04-24 Pfizer Ltd Compounds useful in therapy
AU2003256793A1 (en) * 2002-08-20 2004-03-11 Eli Lilly And Company Substituted azepines as histamine h3 receptor antagonists, preparation and therapeutic uses
GB0408083D0 (en) * 2004-04-08 2004-05-12 Glaxo Group Ltd Novel compounds
FR2870846B1 (fr) * 2004-05-25 2006-08-04 Sanofi Synthelabo Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique

Also Published As

Publication number Publication date
CA2630655C (fr) 2014-08-26
UY29971A1 (es) 2007-06-29
HK1126200A1 (en) 2009-08-28
IL191214A (en) 2012-07-31
BRPI0618971A2 (pt) 2011-09-20
SI1960387T1 (sl) 2012-03-30
CY1112386T1 (el) 2015-12-09
US7678807B2 (en) 2010-03-16
EP1960387A1 (de) 2008-08-27
KR20080076910A (ko) 2008-08-20
AU2006316706A1 (en) 2007-05-31
US20080269199A1 (en) 2008-10-30
RU2418794C2 (ru) 2011-05-20
RU2008125136A (ru) 2009-12-27
AR057615A1 (es) 2007-12-05
CN101312961A (zh) 2008-11-26
PE20070827A1 (es) 2007-08-17
PT1960387E (pt) 2012-02-09
JP2009517357A (ja) 2009-04-30
EP1790646A1 (de) 2007-05-30
ES2376894T3 (es) 2012-03-20
WO2007060027A1 (fr) 2007-05-31
CN101312961B (zh) 2012-04-11
TW200738681A (en) 2007-10-16
PL1960387T3 (pl) 2012-03-30
GT200600490A (es) 2007-07-06
JP5165578B2 (ja) 2013-03-21
EP1960387B1 (de) 2011-11-02
CA2630655A1 (fr) 2007-05-31
AU2006316706B2 (en) 2012-05-03
KR101386318B1 (ko) 2014-04-17
DOP2006000253A (es) 2007-07-15
DK1960387T3 (da) 2012-02-27

Similar Documents

Publication Publication Date Title
ATE467633T1 (de) 2-aryl-6-phenylimidazoä1,2-aüpyridin-derivate, ihre herstellung und therapeutische verwendung
DE122012000018I1 (de) Benzimidazolderivate und ihre verwendung als antagonisten des a II rezeptors.
DE602005027307D1 (de) Arylanilinderivate als agonisten des beta2-adrenergen rezeptors
EP2030974A4 (de) Heterozyklische nichtnukleosidverbindungen, ihre herstellung, pharmazeutische zusammensetzung und ihre verwendung als antivirale mittel
IL189499A (en) Use of 2,4-diaminopyrimidines or 4-aminopyrimidines for the preparation of a medicament for the treatment of a respiratory disease mediated by a p2x3 or p2x2/3 receptor antagonist
ATE520686T1 (de) Azabicycloä3.1.0ühexanderivate und ihre verwendung als modulatoren des dopamin-d3- rezeptors
ATE461932T1 (de) Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors
ATE395342T1 (de) 2-carbamid-4-phenylthiazol-derivate, deren herstellung und therapeutische verwendung
NO345064B1 (no) Anvendelse av kombinasjonslegemidler, omfattende antimykotika
ATE530527T1 (de) 5,6-bisaryl-2-pyridin-carboxamid-derivate sowie ihre herstellung und anwendung in therapeutika als urotensin-ii-rezeptor-antagonisten
DE602005002470D1 (de) 1-aminophthalazinderivate, deren herstellung und deren therapeutische verwendung
ATE553082T1 (de) 5,6-bisaryl-2-pyridin-carboxamid-derivate sowie ihre herstellung und anwendung in therapeutika als urotensin-ii-rezeptor-antagonisten
ATE494290T1 (de) Substituierte 2,5-dihydro-3h-pyrazol-ä4,3-cü- pyridazin-3-on-derivate, ihre herstellung und ihre verwendung als cannibinoid-cb1- rezeptorliganden
ATE512970T1 (de) Dimere von artemisininderivaten, deren herstellung und deren therapeutische verwendung
CY2016040I2 (el) Επιλογες θεραπειας για τη νοσο του fabry
ATE421511T1 (de) Indol-3-carbonyl-spiro-piperidinderivate als antagonisten des v1a-rezeptors
ATE502035T1 (de) 2-amido-4-phenylthiazol-derivate, ihre herstellung und ihre therapeutische verwendung
ATE540023T1 (de) Neuartige 3-aminoalkyl-1,3-dihydro-2h-indol-2-on- derivate, ihre herstellung und therapeutische verwendung
SI1863476T1 (sl) Kombinacija antiholinergikov in antagonistov receptorja levkotriena za zdravljenje respiratornih bolezni
DE602004014772D1 (de) Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptors
ATE459608T1 (de) Oxopiperidinderivate, ihre herstellung und therapeutische verwendung
DE602007010179D1 (de) Piperidinylaminopyridazine und ihre verwendung als schnelldissoziierende antagonisten des dopamin-2-rezeptors
IL181819A (en) Use of benzo-fused compounds for the preparation of a medicament and methods making use of said compounds
ATE520654T1 (de) Polypyrrol-derivate, ihre herstellung und ihre therapeutische verwendung
DE602006001590D1 (de) 7-(2-(4-(3-trifluormethylphenyl)-1,2,3,6-tetrahydropyrid-1-yl)ethyl)isochinolin-besylatsalz, dessen herstellung und dessen therapeutische verwendung